FDA OKs Amitiza for treatment of IBS-C

Apr 30, 2008

The U.S. Food and Drug Administration announced approval of Amitiza (lubiprostone) to treat constipation associated with irritable bowel syndrome.

The FDA said it approved Amitiza for use by adult women aged 18 and over, making the drug the only FDA-approved treatment for IBS-C available in the United States.

Irritable bowel syndrome is a characterized by cramping, abdominal pain, bloating, constipation and diarrhea. It causes a great deal of discomfort and distress to its sufferers, but affects at least twice as many women as men.

"For some people IBS can be quite disabling, making it difficult for them to fully participate in everyday activities," said Dr. Julie Beitz, director of the FDA's Office of Drug Evaluation III. "This drug represents an important step in helping to provide medical relief from their symptoms."

The efficacy of Amitiza in men wasn't conclusively demonstrated for IBS-C and the drug isn't approved for use by children or men. The FDA said it also approved Amitiza for the treatment of chronic idiopathic constipation.

Amitiza is manufactured by Sucampo Pharmaceuticals of Bethesda, Md., and Takeda Pharmaceuticals America Inc. of Deerfield, Ill.

Copyright 2008 by United Press International

Explore further: Targeting drugs to reduce side effects

add to favorites email to friend print save as pdf

Related Stories

Zynga founder Pincus leaving operations role

10 hours ago

Online game maker Zynga says company founder Mark Pincus is stepping down as chief product officer, less than a year after he was replaced as the company's CEO.

First-of-its-kind NASA space-weather project

10 hours ago

A NASA scientist is launching a one-to-two-year pilot project this summer that takes advantage of U.S. high-voltage power transmission lines to measure a phenomenon that has caused widespread power outages ...

US urged to drop India WTO case on solar

11 hours ago

Environmentalists Wednesday urged the United States to drop plans to haul India to the WTO to open its solar market, saying the action would hurt the fight against climate change.

Recommended for you

FDA proposes accelerated medical device approval plan

14 hours ago

(HealthDay)—The U.S. Food and Drug Administration has proposed a new program that would provide expedited access to high-risk medical devices intended for patients with serious conditions whose medical ...

Targeting drugs to reduce side effects

19 hours ago

(Medical Xpress)—Consider ice cream – the base of which is frozen cream. Ingredients are then added to make different flavours. All these flavours are distinctly different but are created from the same foundation.

User comments : 0

More news stories